KNG1 / BDK / Kininogen-1 Recombinant Protein | KNG1 recombinant protein

Recombinant Human KNG1 / BDK / Kininogen-1 Protein (His tag)

Cat. Num. AAA2546199

• Gene Names: KNG1; BK; BDK; KNG
• Purity: > 85 % as determined by SDS-PAGE
• Synonyms: KNG1 / BDK / Kininogen-1; Recombinant Human KNG1 / BDK / Kininogen-1 Protein (His tag); FLJ14993; TNFRSF19L; KNG1 recombinant protein

• Host: Human Cells
• Purity/Purification: > 85 % as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile 25mM Tris, 100mM NaCl, pH 7.5
• Sequence Length: 644

• Application Notes: The recombinant human KNG1 consists of 637 amino acids and has a predicted molecular mass of 71.3 kDa. As a result of glycosylation, the apparent molecular mass of rhKNG1 is approximately 100-110 kDa in SDS-PAGE under reducing conditions.
• Predicted N Terminal: Gln 19
• Endotoxin: < 1.0 EU per mug of the protein as determined by the LAL method
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -70 degree C

SDS-PAGE

Related Product Information for KNG1 recombinant protein

Background: Mouse kininogen-1, also known as high molecular weight kininogen, williams-Fitzgerald-Flaujeac factor, Alpha-2-thiol proteinase inhibitor, Fitzgerald factor, KNG1 and BDK, is a secreted protein which contains three cystatin domains. Kininogen-1 / KNG1 is a protein from the blood coagulation system as well as the kinin-kallikrein system. It is a protein that adsorbs to the surface of biomaterials that come in contact with blood. Kininogen-1 / KNG1 circulates throughout the blood and quickly adsorbs to the material surfaces. Kininogen-1 / KNG1 is one of the early participants of the intrinsic pathway of coagulation, together with Factor XII (Hageman factor) and prekallikrein. Kininogen-1 / KNG1 is one of the kininogens, a class of proteins. As with many other coagulation proteins, the protein was initially named after the patients in whom deficiency was first observed. When the clinical data were combined, it turned out that all patients, in fact, had a deficiency of the same protein. Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) which is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.

Description: A DNA sequence encoding the human KNG1 isoform 1 (NP_001095886.1) (Gln 19-Ser 644) was fused with a polyhistidine tag at the C-terminus, and a signal peptide at the N-terminus.

NCBI and Uniprot Product Information

• NCBI GI #: 156231037
• NCBI GeneID: 3827
• NCBI Accession #: NP_001095886.1
• NCBI GenBank Nucleotide #: NM_001102416.2
• UniProt Accession #: P01042; P01043; Q53EQ0; Q6PAU9; Q7M4P1; A8K474; B2RCR2; C9JEX1
• Molecular Weight: 43,822 Da
• NCBI Official Full Name: kininogen-1 isoform 1
• NCBI Official Synonym Full Names: kininogen 1
• NCBI Official Symbol: KNG1
• NCBI Official Synonym Symbols: BK; BDK; KNG
• NCBI Protein Information: kininogen-1
• UniProt Protein Name: Kininogen-1
• Protein Family: Kininogen
• UniProt Gene Name: KNG1
• UniProt Synonym Gene Names: BDK; KNG; HMWK

NCBI Description

This gene uses alternative splicing to generate two different proteins- high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing numerous physiological effects, is released from HMWK. Bradykinin also functions as an antimicrobial peptide with antibacterial and antifungal activity. In contrast to HMWK, LMWK is not involved in blood coagulation. Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Nov 2014]

Uniprot Description

1 Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.